KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Earnings for KalVista Pharmaceuticals, Inc. (KALV)
Earnings in 2024 (TTM): $-126,644,000
According to KalVista Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-126,644,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of KalVista Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-126,644,000 | $-126,644,000 |
| 2023 | $-92,907,000 | $-74,853,000 |
| 2022 | $-82,339,000 | $-68,512,000 |
| 2021 | $-46,244,000 | $-44,494,000 |
| 2020 | $-29,240,000 | $-29,116,000 |
| 2019 | $-20,692,000 | $-20,816,000 |
| 2018 | $-15,805,000 | $-15,805,000 |
| 2017 | $-18,603,000 | $-18,603,000 |
| 2016 | $-11,436,000 | $-11,436,000 |
| 2015 | $-7,226,000 | $-7,226,000 |
| 2014 | $-5,678,000 | $-5,678,000 |
| 2013 | $-2,053,000 | $-2,053,000 |